Meningococcal Vaccination, Meningococcal conjugate or
MenACWY vaccines; Menactra®, Menveo® Vaccines can help prevent meningococcal disease,
which is any type of illness caused by Neisseria meningitidis bacteria.
Menveo® Manufacturer By GlaxoSmithKline
Menactra® Manufacturer By SanofiPastuer
MenACWY Vaccine is used to
prevent meningococcal disease. This is indicated for active immunization to
prevent invasive meningococcal disease caused by Neisseria meningitidis
serogroups A, C, Y, and W-135. does not prevent N. meningitidis serogroup B
infections.
How is MenACWY Vaccine given?
Vaccine is recommended in children (from 2 years of age),
adolescents, and adults to prevent invasive meningococcal disease. CDC
recommends 2 doses of MenACWY—a primary dose at age 11-12 and a booster at
16—for all adolescents. It is approved for use in individuals 9 months through
55 years of age.
A single booster dose may be given to individuals 15
through 55 years of age at continued risk for meningococcal disease, if at
least 4 to 6 years have elapsed since the prior dose. Do not administer this
product intravenously, subcutaneously, or intradermally.
The use of this vaccine should be in accordance with
official recommendations. It is given by a healthcare professional. It is
important to receive all the doses of the vaccine to be effective.
To make sure the vaccine is safe,
before receiving the vaccine, it is important to let the doctor know if you
have any other illnesses. You should also tell the doctor about all the
medicines you are taking. Pregnant and breastfeeding mothers should consult and
seek advice from their doctor before receiving the vaccine.
